Source:http://linkedlifedata.com/resource/pubmed/id/16417583
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2006-1-31
|
pubmed:abstractText |
This study was designed to investigate the neuroprotective effect of intrinsic and extrinsic erythropoietin (EPO) against hypoxia/ischemia, and determine the optimal time-window with respect to the EPO-induced neuroprotection. Experiments were conducted using primary mixed neuronal/astrocytic cultures and neuron-rich cultures. Hypoxia (2%) induces hypoxia-inducible factor-1alpha (HIF-1alpha) activity followed by strong EPO expression in mixed cultures and weak expression in neuron-rich cultures as documented by both western blot and RT-PCR. Immunoreactive EPO was strongly detected in astrocytes, whereas EPOR was only detected in neurons. Neurons were significantly damaged in neuron-rich cultures but were distinctly rescued in mixed cultures. Application of recombinant human EPO (rhEPO) (0.1 U/mL) within 6 h before or after hypoxia significantly increased neuronal survival compared with no rhEPO treatment. Application of rhEPO after onset of reoxygenation achieved the maximal neuronal protection against ischemia/reperfusion injury (6 h hypoxia followed 24 h reoxygenation). Our results indicate that HIF-1alpha induces EPO gene released by astrocytes and acts as an essential mediator of neuroprotection, prove the protective role of intrinsic astrocytic-neuronal signaling pathway in hypoxic/ischemic injury and demonstrate an optimal therapeutic time-window of extrinsic rhEPO in ischemia/reperfusion injury in vitro. The results point to the potential beneficial effects of HIF-1alpha and EPO for the possible treatment of stroke.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0022-3042
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
96
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1101-10
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:16417583-Animals,
pubmed-meshheading:16417583-Brain Ischemia,
pubmed-meshheading:16417583-Cells, Cultured,
pubmed-meshheading:16417583-Cerebral Cortex,
pubmed-meshheading:16417583-Erythropoietin,
pubmed-meshheading:16417583-Humans,
pubmed-meshheading:16417583-Neurons,
pubmed-meshheading:16417583-Neuroprotective Agents,
pubmed-meshheading:16417583-Rats,
pubmed-meshheading:16417583-Rats, Wistar,
pubmed-meshheading:16417583-Receptors, Erythropoietin,
pubmed-meshheading:16417583-Recombinant Proteins,
pubmed-meshheading:16417583-Reperfusion Injury
|
pubmed:year |
2006
|
pubmed:articleTitle |
Intrinsic and extrinsic erythropoietin enhances neuroprotection against ischemia and reperfusion injury in vitro.
|
pubmed:affiliation |
Department of Neurology, Juntendo University of School of Medicine, Bunkyo-ku, Tokyo, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|